TriangleHEALTH PROFESSIONAL · SOURCE READING
Ofatumumab
Source: Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Ofatumumab is a humanized anti-CD20 monoclonal antibody.
Evidence (ofatumumab alone and in combination with chlorambucil):
A prospective trial included 474 previously treated patients who attained partial or complete remission to second- or third-line chemotherapy. Patients were randomly assigned to 2 years of maintenance therapy with ofatumumab versus observation.[32]
Source links and citations
A prospective trial included 474 previously treated patients who attained partial or complete remission to second- or third-line chemotherapy. Patients were randomly assigned to 2 years of maintenance therapy with ofatumumab versus observation.[32]
With a median follow-up of 19 months, median PFS favored the ofatumumab maintenance arm, at 29.4 months versus 15.2 months (HR, 0.50; 95% CI, 0.38–0.66; P < .0001). There was no difference in OS.[32][Level of evidence B1]
Source links and citations
A prospective randomized trial of 447 patients who were previously untreated compared ofatumumab plus chlorambucil with chlorambucil alone.[33]
Source links and citations
A prospective randomized trial of 447 patients who were previously untreated compared ofatumumab plus chlorambucil with chlorambucil alone.[33]
With a median follow-up of 2 years, median PFS favored the ofatumumab plus chlorambucil arm, at 22.4 months versus 13.1 months (HR, 0.57; 95% CI, 0.45–0.72; P = .0001). There was no difference in OS.[33][Level of evidence B1]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice